Modern Approach for Drug Design Towards Alzheimer’s Disease called Multi-Target Directed Drugs

What is it about?

Alzheimer’s disease (AD) is a complex neurodegenerative disorder with a multi-faceted pathogenesis. So far, the therapeutic paradigm “one-compound-one-target” has failed and despite enormous efforts to elucidate the pathophysiology of AD, the disease is still incurable, with all current medicines only being capable to slow up its progress and ameliorate the qualify of life of the patients. The AD involve multiple factors, these factors leading to cognitive and memory impairment, and neuronal death. A recent approach for the rational design of new drug candidates, also called multitarget-directed ligand (MTDL) approach, has gained increasing attention by many research groups, which have developed a variety of hybrid compounds acting simultaneously on diverse biological targets. In this chapter we aimed to show some recent advances during the last decade and examples of the exploitation of MTDL approach in the rational design of novel drug candidate prototypes for the treatment of AD.

Featured Image

Why is it important?

This article show some recent advances during the last decade and examples of the exploitation of MTDL approach in the rational design of novel drug candidate prototypes for the treatment of AD. This is important methodology for treatment of multifactorial diseases